Non-Hodgkin Lymphoma (NHL)

Latest News

Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

By Maggie L. Shaw

April 16th 2025

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.

CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

By Maggie L. Shaw

April 3rd 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

By Mary Caffrey

March 24th 2025

CAR T | Image Credit: © Funny-stock.adobe.com

Overcoming CAR T Manufacturing Failure in LBCL

By Maggie L. Shaw

March 21st 2025

Patients with R/R transformed DLBCL have modest 4-year event free and overall survival rates under 50%, making disease management a persistent challenge | SuriyaPhoto - stock.adobe.com

Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment

March 14th 2025

Continuing Medical Education

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

stem cell transplant text write on blackboard | Image credit: flytoskyft11 - stock.adobe.com

January 30th 2024

Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure

Jared Kaltwasser

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

Patient and doctor | Image Credit: © DragonImages - stock.adobe.com

January 26th 2024

Case Report Highlights Case of Distinct DLBCLs in a Single Patient

Jared Kaltwasser

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

January 25th 2024

What We’re Reading: ACA Sign-Up Surge; Hospitals Fight Climate Change; Secondary Cancers, CAR T Link

A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.

Data analytics | Image Credit: NicoElNino - stock.adobe.com

January 24th 2024

In DLBCL, Refining Patient Stratification an Ongoing Project

Jared Kaltwasser

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

Ibrutinib | Image Credit: CLShebley

January 22nd 2024

Ibrutinib Plus R-CHOP Cost-Effective for Young Patients With ABC-DLBCL

Jared Kaltwasser

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found.

Health care costs graphic | Image credit: wladimir1804 – stock.adobe.com

January 19th 2024

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Hayden E. Klein

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

January 12th 2024

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

January 8th 2024

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

Lymphoma cells | Image credit: LASZLO - stock.adobe.com

September 22nd 2023

Salvage RT Shows Local Control in LBCL After CAR T-Cell Therapy Failure

Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.

Diffuse large B-cell lymphoma | Image credit: David A Litman - stock.adobe.com

September 21st 2023

Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

CT machine | Image credit: MyPixelArtStudios - stock.adobe.com

September 15th 2023

Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL

A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Blood cells | Image credit: Катерина Євтехова - stock.adobe.com

September 7th 2023

Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs

The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.

Blood flowing

August 18th 2023

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

CAR T-cell therapy

August 11th 2023

Axi-Cel Extends Survival vs Standard of Care for R/R LBCL

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

Senior sad man leans on a cane while sitting on sofa: © LIGHTFIELD STUDIOS - stock.adobe.com

August 1st 2023

Despite Novelty, Fluid Overload–Associated LBCL Has Distinguishing Features

Jared Kaltwasser

Investigators said the fact that their patient was 82 years old was one reason to suspect fluid overload–associated large B-cell lymphoma (LBCL).

Doctor holding in his hands two silicone implants. Female patient trying to touch them: © Yakobchuk Olena - stock.adobe.com

July 31st 2023

Amid Increasing Breast Implant–Related EBV+ DLBCL Cases, Researchers Share Insights on the Disease

Jaime Rosenberg

Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).

Blood vial and hepatitis B | Image Credit: © alexskopje - stock.adobe.com

July 29th 2023

Treated Hepatitis B Infection May Be a Positive Prognostic Factor in Patients With DLBCL

Those with the infection who underwent treatment exhibited improved outcomes compared with patients without the infection.

Endocrinology doctor consulting lymphoma patient with sore neck, aching swollen lymph nodes, throat pain, laryngitis, hodgkin symptoms. Healthcare specialist medical appointment in clinic office: © DC Studio - stock.adobe.com

July 27th 2023

Review Details Current Understanding, Future Directions of DLBCL in Patients With HIV

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype in individuals living with HIV.

Heart and DNA Image

July 22nd 2023

In DLBCL Treatment, Cardiovascular Comorbidities Warrant Careful Consideration

Jared Kaltwasser

The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.

Symbol of pancreatic cancer. Purple awareness ribbon: © Vitalii Vodolazskyi - stock.adobe.com

July 18th 2023

In Pancreatic DLBCL, Older Age, Distant Stage, Lack of Surgery Lead to Worse Outcomes

Jared Kaltwasser

Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.

Colorful cell interaction - tumor cell surrounded with immune cells (Generative AI): © Nevio - stock.adobe.com

July 11th 2023

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.

PET/CT is a nuclear medicine device that uses a combination of PET (Positron Emission Tomography) and Computed Tomography technology to diagnose cancer. Brain and nervous system myocardial ischemia: © workphoto - stock.adobe.com

July 8th 2023

Complicated Case of DLBCL Shows Limits of 18F-FDG PET/CT Imaging

Jared Kaltwasser

Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).

White blood cells in leukemia, AI Generative: © Катерина Євтехова - stock.adobe.com

July 5th 2023

Evolutionary Dynamics Drive Behind Outcomes in Late DLBCL Relapses

Jared Kaltwasser

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

June 28th 2023

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.

Finding solutions to complex cases from several perspectives. High angle shot of a group of medical practitioners having a discussion together in a hospital: © Kirsten D/peopleimages.com - stock.adobe.com

June 27th 2023

Patient Complaining of Abdominal Pain Found to Have Unusual Case of DLBCL

Jared Kaltwasser

The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

June 22nd 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Jared Kaltwasser

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

researchers in a lab

June 17th 2023

Epcoritamab Sparks Durable Responses in Phase 1/2 LBCL Trial

Jared Kaltwasser

At a median follow-up of 10.7 months, the overall response rate was 63.1%.

chest pain

June 16th 2023

Investigators Find DLBCL When Probing Apparent Intramural Hematoma

Jared Kaltwasser

The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.

depressed older man sitting with his head in his hand

June 8th 2023

Preexisting Mental Health Disorders Worsen DLBCL Prognosis

Laura Joszt, MA

Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.

science background

June 7th 2023

Review: Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Jared Kaltwasser

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions